Physicochemical Stability Study of Oral Suspension Containing Ruxolitinib in Children with Steroid-Refractory Acute Graft-Versus-Host Disease
Ruxolitinib, used in children with steroid-refractory acute graft-versus-host (GVH) disease, is currently commercially available only as a tablet adult dosage. For the paediatric population, an oral liquid would be an adapted dosage formulation. The aim of this study was to develop ruxolitinib compo...
Saved in:
| Main Authors: | Mélanie Hinterlang, Maria Sebti, Camille Cotteret, Fabrice Vidal, Bénédicte Neven, Salvatore Cisternino, Joël Schlatter |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1155/2022/1931118 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Case Report: Successful treatment of steroid- and ruxolitinib-refractory gastrointestinal acute graft-versus-Host disease with anti-thymocyte globulin
by: Lulu Zhang, et al.
Published: (2025-07-01) -
Ruxolitinib add-on therapy in steroid-refractory graft-vs-host disease following hematopoietic cell transplantation: A single institutional experience
by: Yi-Lun Wang, et al.
Published: (2024-01-01) -
Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease using Simulated Treatment Comparisons
by: Gabriel Tremblay, et al.
Published: (2021-02-01) -
Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease: A giant leap -To start with baby steps
by: Suvir Singh
Published: (2020-01-01) -
Successful Treatment of Refractory Graft-Versus-Host Disease with Ruxolitinib in a Child after Autologous Stem Cell Transplantation
by: Nurşah Eker, et al.
Published: (2022-06-01)